Anaprazole-based versus rabeprazole-based quadruple therapy for Helicobacter pylori eradication: a prospective, multicenter, randomized controlled trial.
5 affiliations
- 1Department of Gastroenterology, The Anqing 116 Hospital, China RongTong Medical Healthcare Group Co. Ltd., Anqing, China.
- 2Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
- 3Department of Gastroenterology, The First People's Hospital of Suqian, Suqian, China.
- 4Department of Gastroenterology, Changzhou Traditional Chinese Medicine Hospital, Changzhou, China.
- 5Department of Gastroenterology, Lianshui County People's Hospital, Huai'an, China.
Abstract
To compare the efficacy and safety of a bismuth-containing quadruple therapy comprising the novel proton pump inhibitor (PPI) anaprazole versus the classical PPI rabeprazole, both combined with amoxicillin and furazolidone, for Helicobacter pylori (H. pylori) eradication. A prospective, multicenter, randomized, open-label, non-inferiority design was employed. Consecutive treatment-naïve patients positive for H. pylori who visited the gastroenterology departments of four hospitals in Jiangsu Province between August 2025 and February 2026 were enrolled. Eligible patients were randomly assigned in a 1:1 ratio to two groups: the anaprazole group (anaprazole 20 mg, amoxicillin 1000 mg, furazolidone 100 mg, and colloidal bismuth pectin 300 mg, twice daily) and the rabeprazole group (rabeprazole 20 mg, amoxicillin 1000 mg, furazolidone 100 mg, and colloidal bismuth pectin 300 mg, twice daily). Both groups received a 14-day treatment course. H. pylori eradication was assessed by ¹³C-urea breath test at 4 weeks after the completion of therapy. A total of 320 patients were enrolled, with 160 in each group. In the intention-to-treat (ITT) analysis, the eradication rate was 81.9% (95% CI: 75.2% to 87.1%) in the anaprazole group and 80.0% (95% CI: 73.1% to 85.5%) in the rabeprazole group, with a difference of 1.9% (95% CI: -6.7% to 10.5%, P=0.67). In the modified intention-to-treat (mITT) analysis, the eradication rates were 89.1% (95% CI: 83.1% to 93.2%) and 88.9% (95% CI: 82.7% to 93.1%), respectively (difference: 0.2%; 95% CI: -7.0% to 7.4%, P=0.95). In the per-protocol (PP) analysis, the eradication rates were 90.9% (95% CI: 85.2% to 94.6%) and 90.0% (95% CI: 83.9% to 94.0%), respectively (difference: 0.9%; 95% CI: -5.8% to 7.6%, P=0.80). Regarding safety, the incidence of adverse events was slightly higher in the anaprazole group compared to the rabeprazole group (22.50% vs. 15.00%), but the difference was not statistically significant (P=0.09). Medication adherence was similar between the two groups (P=0.60). The quadruple regimen consisting of anaprazole combined with amoxicillin, furazolidone, and bismuth is non-inferior to the rabeprazole-based quadruple regimen for the eradication of H. pylori infection. There were no significant differences between the two groups in terms of eradication rate, incidence of adverse reactions, or medication adherence. Anaprazole, as an acid-suppressive agent, achieves satisfactory efficacy in H. pylori eradication therapy and holds promise for clinical application.
Related
- Antimicrobial Resistance-Stratified Efficacy of Vonoprazan, Clarithromycin, and Metronidazole Therapy for Helicobacter pylori Eradication in Penicillin-Allergic Patients: A Single-Arm Prospective Interventional Study.
- Helicobacter pylori Infection in Rome IV Functional Dyspepsia: Association with the Epigastric Pain Syndrome Phenotype and Long-Term Response to Eradication
- Efficacy and Safety of Tegoprazan–Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis With Trial Sequential Analysis of Randomized Controlled Trials
- Incidentally Detected Persistent Helicobacter heilmannii Gastritis in a Korean Woman With a Normal Endoscopic Examination: Successful Eradication After Salvage Therapy
- Gastric Cancer: Global Epidemiology, Risk Factors, Helicobacter pylori Eradication, and Risk-Based Screening
BibTeX
@article{wang2026anaprazolebased,
title = {{Anaprazole-based versus rabeprazole-based quadruple therapy for Helicobacter pylori eradication: a prospective, multicenter, randomized controlled trial.}},
author = {Xiujuan Wang and Haocheng Wang and Yan Wang and Lu Shen and Guiqin Li and Jijun Zhu and Changhui Li and Jiahuan Gao and Zhenyu Zhang},
journal = {Frontiers in cellular and infection microbiology},
year = {2026},
month = oct,
doi = {10.3389/fcimb.2026.1972507},
url = {https://europepmc.org/article/MED/42952689},
note = {CC BY},
}
RIS
TY - JOUR
TI - Anaprazole-based versus rabeprazole-based quadruple therapy for Helicobacter pylori eradication: a prospective, multicenter, randomized controlled trial.
AU - Xiujuan Wang
AU - Haocheng Wang
AU - Yan Wang
AU - Lu Shen
AU - Guiqin Li
AU - Jijun Zhu
AU - Changhui Li
AU - Jiahuan Gao
AU - Zhenyu Zhang
PY - 2026
DA - 2026/10/14
JO - Frontiers in cellular and infection microbiology
DO - 10.3389/fcimb.2026.1972507
UR - https://europepmc.org/article/MED/42952689
AB - To compare the efficacy and safety of a bismuth-containing quadruple therapy comprising the novel proton pump inhibitor (PPI) anaprazole versus the classical PPI rabeprazole, both combined with amoxicillin and furazolidone, for Helicobacter pylori (H. pylori) eradication. A prospective, multicenter, randomized, open-label, non-inferiority design was employed. Consecutive treatment-naïve patients positive for H. pylori who visited the gastroenterology departments of four hospitals in Jiangsu Province between August 2025 and February 2026 were enrolled. Eligible patients were randomly assigned in a 1:1 ratio to two groups: the anaprazole group (anaprazole 20 mg, amoxicillin 1000 mg, furazolidone 100 mg, and colloidal bismuth pectin 300 mg, twice daily) and the rabeprazole group (rabeprazole 20 mg, amoxicillin 1000 mg, furazolidone 100 mg, and colloidal bismuth pectin 300 mg, twice daily). Both groups received a 14-day treatment course. H. pylori eradication was assessed by ¹³C-urea breath test at 4 weeks after the completion of therapy. A total of 320 patients were enrolled, with 160 in each group. In the intention-to-treat (ITT) analysis, the eradication rate was 81.9% (95% CI: 75.2% to 87.1%) in the anaprazole group and 80.0% (95% CI: 73.1% to 85.5%) in the rabeprazole group, with a difference of 1.9% (95% CI: -6.7% to 10.5%, P=0.67). In the modified intention-to-treat (mITT) analysis, the eradication rates were 89.1% (95% CI: 83.1% to 93.2%) and 88.9% (95% CI: 82.7% to 93.1%), respectively (difference: 0.2%; 95% CI: -7.0% to 7.4%, P=0.95). In the per-protocol (PP) analysis, the eradication rates were 90.9% (95% CI: 85.2% to 94.6%) and 90.0% (95% CI: 83.9% to 94.0%), respectively (difference: 0.9%; 95% CI: -5.8% to 7.6%, P=0.80). Regarding safety, the incidence of adverse events was slightly higher in the anaprazole group compared to the rabeprazole group (22.50% vs. 15.00%), but the difference was not statistically significant (P=0.09). Medication adherence was similar between the two groups (P=0.60). The quadruple regimen consisting of anaprazole combined with amoxicillin, furazolidone, and bismuth is non-inferior to the rabeprazole-based quadruple regimen for the eradication of H. pylori infection. There were no significant differences between the two groups in terms of eradication rate, incidence of adverse reactions, or medication adherence. Anaprazole, as an acid-suppressive agent, achieves satisfactory efficacy in H. pylori eradication therapy and holds promise for clinical application.
SN - 2235-2988
ER -